Novo Nordisk reports Q3 results

* Novo Nordisk press release [https://ml-eu.globenewswire.com/Resource/Download/ae93d17e-6c68-433e-ac46-9ea814575af0] (NVO [https://seekingalpha.com/symbol/NVO]): Q3 GAAP EPS of DKK4.55
* Revenue of DKK74.98M (+5.2% Y/Y).
* Net profit decreased by 27% to DKK 20,006 million, and Adjusted net profit increased by 5% to DKK 29,179 million. Diluted earnings per share decreased by 26% to DKK 4.50.
* Novo Nordisk now expects financial items (net) for 2025 to amount to a gain of around DKK 2.6 billion. This is driven by gains on hedged currencies, mainly the US dollar, countered by interest expenses related to funding of the debt-financed Catalent transaction.
* Sales growth is now expected to be 8-11% at CER. Included in the full-year guidance are positive impacts related to US gross-to-net sales adjustments earlier in 2025.

MORE ON NOVO NORDISK

* Novo Nordisk: Governance Shakeup Amid Broader Headwinds [https://seekingalpha.com/article/4836856-novo-nordisk-stock-governance-shakeup-amid-broader-headwinds]
* Novo Nordisk: Desperate Move [https://seekingalpha.com/article/4836823-novo-nordisk-desperate-move]
* Novo: Risks Revisited And Potential Metsera Deal [https://seekingalpha.com/article/4835853-novo-risks-revisited-and-potential-metsera-deal]
* Novo Nordisk cuts 2025 forecast again, cites slower sales of Wegovy and Ozempic [https://seekingalpha.com/news/4515402-novo-nordisk-cuts-2025-forecast-again-cites-slower-sales-of-wegovy-and-ozempic]
* Eli Lilly, Novo reportedly nearing U.S. deals for obesity drug prices (update) [https://seekingalpha.com/news/4514411-eli-lilly-novo-us-deals-obesity-drug-prices]